Reassuring the CVsafety of Sulfonylureas : AReview article to readdress the CVsafety of Modern Sulfonylureas post CAROLINAtrial

摘要

For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. One such trial is the CAROLINA trial where the trial finally put concerns about sulfonylureas' cardiovascular safety to rest. Considering their efficacy, safety, pleiotropic benefits, and low cost of therapy, SUs should be considered as recommended therapy for the treatment of diabetes.